Ondine Biomedical Inc. Ondine CEO increases shareholding
04 Febbraio 2025 - 9:30AM
RNS Regulatory News
RNS Number : 7578V
Ondine Biomedical Inc.
04 February 2025
ONDINE BIOMEDICAL
INC.
("Ondine
Biomedical", "Ondine", or the "Company")
Ondine CEO increases
shareholding in Company as Phase 3 clinical trial
progresses
Ondine Biomedical Inc. (AIM: OBI), a
Canadian life sciences company pioneering light-activated
antimicrobial treatments, announces that The Pennycook Family
Trust, controlled by Carolyn Cross, CEO, and Robert Cross, husband
of Carolyn Cross, has purchased 149,225 shares ("Common Shares") in
the Company at a price of 12.5 pence per Common Share on 03
February 2025.
Following this transaction, Carolyn
Cross and Robert Cross, directly and indirectly, hold
156,314,029 Common Shares representing 35.3621% of the issued
share capital of the Company.
Enquiries:
|
Ondine Biomedical
Inc.
|
www.ondinebio.com
|
|
Carolyn Cross, CEO
|
Via Vane Percy &
Roberts
|
|
Strand Hanson Limited (Nominated & Financial
Adviser)
|
|
|
James Harris, Richard
Johnson
|
+44 (0)20 7409 3494
|
|
|
|
|
RBC
Capital Markets (Broker)
|
|
|
Rupert Walford, Kathryn
Deegan
|
+44 (0)20 7653 4000
|
|
|
|
|
Vane Percy & Roberts (Media Contact)
|
|
|
Simon Vane Percy, Amanda
Bernard
|
+44 (0)77 1000 5910
|
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian
life sciences company and leader in light-activated antimicrobial
therapies (also known as 'photodisinfection'). Ondine has a
pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of
development.
Ondine's nasal photodisinfection
system has a CE mark in Europe and is approved in Canada and
several other countries under the name Steriwave®. In
the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical
indications such as chronic sinusitis, ventilator-associated
pneumonia, burns and other indications.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
|
1.
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Carolyn Cross and her PCA
|
|
2.
|
Reason for the Notification
|
|
a)
|
Position/status
|
Chief Executive Officer
(PDMR)
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Ondine Biomedical Inc.
|
|
b)
|
LEI
|
9845005B69E07CGF4A56
|
|
4.
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the Financial
instrument, type of instrument
|
Common shares
|
|
Identification code
|
ISIN: CA68234M2058
|
|
b)
|
Nature of the transaction
|
Share purchase
|
|
c)
|
Price(s) and volume(s)
|
149,225 shares at 12.5 pence
each
|
|
d)
|
Aggregated information:
·Aggregated volume
·Price
|
N/A
|
|
e)
|
Date of the transaction
|
03 February 2025
|
|
f)
|
Place of the transaction
|
AIM
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHTIMMTMTJMMJA
Grafico Azioni Ondine Biomedical (LSE:OBI)
Storico
Da Gen 2025 a Feb 2025
Grafico Azioni Ondine Biomedical (LSE:OBI)
Storico
Da Feb 2024 a Feb 2025
